Saturday 17 October 2026
Export TVRD’s income statement to Excel — free account
Tvardi Therapeutics, Inc.
TVRD Healthcare Biotechnology
In the quarter to June 2026, revenue grew 20.3%, EPS fell 235.3% and free cash flow fell 57.3%, each against the same quarter a year earlier.
1.01
0.06
−5.61%
Follow TVRD
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 168.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | 3 | 2 | 3 | 2 | 5 | 2 | 4 | 4 | 2 |
P/S ratio |
— | 4.42 | 1.95 | 14.03 | 4.57 | 5.31 | 34.55 | 32.43 | 401.64 | 3,094.42 |
Altman Z-Score |
— | (5.15) | (9.42) | 9.99 | 15.90 | 18.74 | 5.64 | 2.27 | 18.28 | 5.96 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | (10.69) | (18.63) | (1.01) | 7.60 | 11.49 | (1.13) | (0.91) | 3.24 | (5.24) |
Beneish M-Score |
— | (3.66) | (3.39) | (1.22) | (2.84) | 1.40 | (1.55) | 12.86 | 5.26 | 67.91 |
P/Operating CF |
— | (9.78) | (2.36) | (24.99) | (495.96) | 8.73 | (22.05) | (19.14) | (35.09) | (20.18) |
P/B ratio |
— | 0.00 | 0.72 | 3.70 | 2.71 | 2.88 | 3.68 | 3.49 | 4.61 | 5.25 |
Price to Tangible BV |
— | 0.00 | 0.72 | 3.70 | 2.71 | 2.88 | 3.68 | 3.49 | 4.61 | 5.25 |
EV/Sales |
— | 7.03 | (1.15) | 11.26 | 3.56 | 4.21 | 28.40 | 23.22 | 308.80 | 2,408.65 |
EV/EBITDA |
— | 0.00 | 0.20 | 0.00 | 0.00 | 86.82 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | (4.11) | 0.26 | (5.99) | (8.01) | (103.70) | (5.17) | (14.97) | (5.62) | (4.37) |
EV/FCF |
— | (3.50) | 0.26 | (5.98) | (8.02) | (97.50) | (5.17) | (14.92) | (5.61) | (4.31) |
Quick Ratio |
2.79 | 3.48 | 4.11 | 6.41 | 9.55 | 9.90 | 3.66 | 4.04 | 10.98 | 5.20 |
Current Ratio |
2.86 | 3.06 | 4.54 | 7.20 | 9.84 | 10.55 | 3.86 | 4.16 | 11.18 | 5.33 |
Net Debt/EBITDA |
1.15 | 0.05 | 0.85 | 1.70 | 1.91 | (27.04) | 1.35 | 2.05 | 1.55 | 1.03 |
Debt/Assets |
0.00% | 85.97% | 0.00% | 0.00% | 0.78% | 1.35% | 1.44% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | (0.33) | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.09 | 0.14 | 0.20 | 0.09 | 0.54 | 0.09 | 0.09 | 0.01 | 0.00 |
Operating CF/Net income |
1.29 | 0.62 | 0.78 | 0.92 | 0.68 | (0.65) | 1.03 | 0.30 | 0.94 | 0.83 |
Capex/Depreciation |
0.00 | (11.01) | (1.23) | (0.02) | 0.01 | (0.30) | 0.03 | 0.05 | 0.20 | (0.57) |
| 51.90% | 172.69% | (109.80%) | (44.25%) | (37.12%) | 3.86% | (66.41%) | (67.16%) | (84.54%) | (73.54%) | |
| (54.15%) | (36.51%) | (76.94%) | (39.82%) | (34.13%) | 3.34% | (50.20%) | (51.43%) | (72.28%) | (65.57%) | |
ROIC |
0.00% | 0.00% | 0.00% | (421.75%) | (89.22%) | 4.69% | (199.09%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(88.64%) | (137.35%) | (126.23%) | (58.59%) | (56.58%) | 4.74% | (86.16%) | (57.57%) | (66.26%) | (111.17%) |
Average Days of Receivables |
— | 229.88 | 69.93 | 38.82 | 18.26 | 5.58 | 32.80 | 43.09 | 342.16 | 3,985.29 |
Research and Development Expense of Revenue |
0.00% | 331.37% | 517.50% | 219.45% | 359.13% | 79.84% | 572.36% | 560.78% | 5,326.45% | 57,270.93% |
Selling, General and Administrative Expense of Revenue |
0.00% | 62.45% | 132.48% | 72.27% | 127.71% | 16.17% | 89.23% | 113.74% | 1,303.18% | 10,736.05% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 4.47% | 65.48% | 42.36% | 90.26% | 10.98% | 63.20% | 70.37% | 635.89% | 3,255.81% |
Graham Net Nets |
— | (2.00) | 1.16 | 0.25 | 0.25 | 0.24 | 0.17 | 0.24 | 0.21 | 0.18 |
Graham Number |
— | 95.07 | 0.00 | 0.00 | 0.00 | 117.46 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (61.80%) | (288.46%) | (14.53%) | (14.21%) | 0.60% | (15.46%) | (15.85%) | (14.88%) | (21.53%) |
Free Cash Flow Yield |
— | (45.37%) | (230.73%) | (13.41%) | (9.73%) | (0.81%) | (15.90%) | (4.80%) | (13.70%) | (18.07%) |
Revenue per Share |
0.00 | 2.77 | 13.94 | 28.09 | 16.35 | 102.61 | 16.79 | 13.52 | 1.05 | 0.11 |
Operating CF per Share |
(3.17) | (7.11) | (61.23) | (52.83) | (42.67) | (4.17) | (92.20) | (22.38) | (63.29) | (62.56) |
Capex per Share |
0.00 | (0.41) | (1.58) | (0.03) | 0.02 | (0.27) | (0.02) | (0.07) | (0.02) | (0.95) |
Free Cash Flow per Share |
(3.17) | (7.52) | (62.81) | (52.86) | (42.65) | (4.43) | (92.21) | (22.45) | (63.31) | (63.50) |
Cash per Share |
4.15 | 12.28 | 67.27 | 97.84 | 118.62 | 137.44 | 130.84 | 162.31 | 106.86 | 77.87 |
Shareholders Equity per Share |
2.82 | (35.40) | 37.96 | 106.55 | 161.57 | 189.15 | 157.60 | 134.10 | 100.17 | 66.97 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.82 | (35.40) | 37.96 | 106.55 | 161.57 | 189.15 | 157.60 | 134.10 | 100.17 | 66.97 |
Free Cash Flow |
(23.50) | (19.35) | (94.45) | (78.77) | (60.06) | (5.84) | (109.24) | (22.37) | (54.84) | (48.10) |
Working Capital |
20.50 | 21.32 | 90.57 | 145.45 | 155.67 | 176.58 | 122.76 | 127.69 | 86.55 | 49.91 |
Capital Expenditures |
— | (1.05) | (2.37) | (0.04) | 0.03 | (0.35) | (0.02) | (0.07) | (0.02) | (0.72) |
Net Current Asset Value |
20.41 | (94.64) | 47.40 | 145.45 | 153.76 | 172.91 | 119.41 | 110.95 | 84.83 | 48.34 |
EV/EBIT |
— | 0.00 | 0.20 | 0.00 | 0.00 | 105.67 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.15 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 8.34 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 133.15 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(2.02) | 1.13 | 0.58 | 4.54 | 3.83 | 1.39 | (0.83) | (1.65) | (0.07) | 0.77 |
Cash ROIC |
(45.40%) | 66.14% | (59.69%) | (25.86%) | (15.15%) | (1.35%) | (31.66%) | (7.57%) | (30.58%) | (43.84%) |
Accounts Receivable Turnover |
— | 1.68 | 4.95 | 14.94 | 14.32 | 70.15 | 11.78 | 11.02 | 1.02 | 0.12 |
Accounts Payable Turnover |
0.00 | 0.11 | 0.00 | 0.95 | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.33 | 2.37 | 2.93 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 1,286.92 | 0.00 | 482.45 | 1,321.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 529.84 | 166.77 | 119.71 | 606.92 | — | — | — | — | — |
Average Receivables |
— | 4.26 | 4.24 | 2.80 | 1.61 | 1.93 | 1.69 | 1.22 | 0.90 | 0.70 |
Average Payables |
2.70 | 5.90 | — | 7.61 | 5.26 | 7.00 | 6.74 | 4.10 | 4.28 | 4.28 |
Average Inventory |
— | 1.86 | 2.60 | 2.48 | — | — | — | — | — | — |
Average Assets |
33.64 | 80.52 | 154.04 | 214.65 | 259.11 | 252.06 | 211.89 | 143.91 | 80.42 | 87.36 |
Average Common Equity |
(35.09) | (17.02) | 107.93 | 193.15 | 238.26 | 217.86 | 160.17 | 110.21 | 68.75 | 77.88 |
Columns are period end dates